Diagnostik und Therapie schlafbezogener Atmungsstörungen im Zusammenhang mit der Corona‑Pandemie

Author(s): N. Büchner ¹ ^, , H. Woehrle ² , D. Dellweg ³ , A. Wiater ⁴ , P. Young ⁵ , H. Hein ⁶ , W. Randerath ⁷ ^, ⁸ , Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e. V. (DGP), Deutsche Gesellschaft für Schlafforschung und Schlafmedizin (DGSM)

Publication date (Electronic): 22 June 2020

Journal: Somnologie

Publisher: Springer Medizin

Keywords: Coronavirus-Pandemie, SARS-CoV2, Schlaflabor, Schlafapnoe, Schlafbezogene Atmungsstörungen, Coronavirs pandemic, SARS-CoV2, Sleep laboratory, Sleep apnea, Sleep related breathing disorders

Read this article at

ScienceOpenPublisher PMC

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Bei der Erbringung schlafmedizinischer Leistungen im Zusammenhang mit der Corona-Pandemie sind besondere Aspekte zu berücksichtigen. Trotz aller vorbeugender Maßnahmen muss aufgrund der hohen Dunkelziffer mit SARS-CoV2-Kontakten im Schlaflabor gerechnet und entsprechende Vorkehrungen getroffen werden. Die Fortführung bzw. Wiederaufnahme schlafmedizinischer Leistungen unter den gebotenen Hygienemaßnahmen ist dennoch dringend anzustreben zur Vermeidung medizinischer und psychosozialer Komplikationen. Es gibt keine gesicherten Hinweise für eine Verschlechterung der COVID-19 durch eine CPAP-Therapie. Grundsätzlich kann die Anwendung einer Überdrucktherapie über verschiedene Maskensysteme mit der Bildung einer infektiösen Aerosolwolke einhergehen. Bei bestätigter Infektion mit SARS-CoV-2 sollte im ambulanten Umfeld eine vorbestehende Maskentherapie unter Einhaltung der Vorgaben des RKI zur häuslichen Isolierung fortgeführt werden, da eine Therapiebeendigung mit einer zusätzlichen kardiopulmonalen Belastung durch die unbehandelte schlafbezogene Atmungsstörung einhergeht. Mit geeigneter persönlicher Schutzausrüstung (Augenschutz, FFP2/FFP3-Maske, Kittel) kann eine PAP-Therapie nach jetzigem Kenntnisstand vom Personal ohne erhöhtes Infektionsrisiko durchgeführt werden.

Dieses gemeinsame Positionspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP) und der Deutschen Gesellschaft für Schlafmedizin (DGSM) beinhaltet konkrete Empfehlungen zur Durchführung schlafmedizinischer Diagnostik und Therapie im Umfeld der Corona-Pandemie.

Translated abstract

When providing sleep medical services special aspects must be taken into account in the context of the coronavirus pandemic. Despite all prevention, due to the high number of unrecognized cases, SARS-CoV2 contacts in the sleep laboratory must be expected and appropriate precautions are necessary. Nevertheless, the continuation or resumption of sleep medical services under the appropriate hygiene measures is strongly recommended to avoid medical and psychosocial complications. There is no evidence for a deterioration of COVID-19 through CPAP therapy. In principle, the application of positive pressure therapy via various mask systems can be accompanied by the formation of infectious aerosols. In the case of confirmed infection with SARS-CoV2, a pre-existing PAP therapy should be continued in an outpatient setting in accordance with the local guidelines for home isolation, since discontinuation of PAP therapy is associated with additional cardiopulmonary complications due to the untreated sleep-related breathing disorder. According to the current state of knowledge inhalation therapy, nasal high-flow (NHF), and PAP therapy can be carried out without increased risk of infection for health care workers (HCW) as long as appropriate personal protective equipment (eye protection, FFP2 or FFP-3 mask, gown) is being used.

This position paper of the German Society for Pneumology and Respiratory Medicine (DGP) and the German Society for Sleep Medicine (DGSM) offers detailed recommendations for the implementation of sleep medicine diagnostics and therapy in the context of the coronavirus pandemic.

Related collections

Most cited references 31

Record: found
Abstract: found
Article: not found

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1

Neeltje van Doremalen, Trenton Bushmaker, Dylan H Morris … (2021)

To the Editor: A novel human coronavirus that is now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (formerly called HCoV-19) emerged in Wuhan, China, in late 2019 and is now causing a pandemic. 1 We analyzed the aerosol and surface stability of SARS-CoV-2 and compared it with SARS-CoV-1, the most closely related human coronavirus. 2 We evaluated the stability of SARS-CoV-2 and SARS-CoV-1 in aerosols and on various surfaces and estimated their decay rates using a Bayesian regression model (see the Methods section in the Supplementary Appendix, available with the full text of this letter at NEJM.org). SARS-CoV-2 nCoV-WA1-2020 (MN985325.1) and SARS-CoV-1 Tor2 (AY274119.3) were the strains used. Aerosols (<5 μm) containing SARS-CoV-2 (105.25 50% tissue-culture infectious dose [TCID50] per milliliter) or SARS-CoV-1 (106.75-7.00 TCID50 per milliliter) were generated with the use of a three-jet Collison nebulizer and fed into a Goldberg drum to create an aerosolized environment. The inoculum resulted in cycle-threshold values between 20 and 22, similar to those observed in samples obtained from the upper and lower respiratory tract in humans. Our data consisted of 10 experimental conditions involving two viruses (SARS-CoV-2 and SARS-CoV-1) in five environmental conditions (aerosols, plastic, stainless steel, copper, and cardboard). All experimental measurements are reported as means across three replicates. SARS-CoV-2 remained viable in aerosols throughout the duration of our experiment (3 hours), with a reduction in infectious titer from 103.5 to 102.7 TCID50 per liter of air. This reduction was similar to that observed with SARS-CoV-1, from 104.3 to 103.5 TCID50 per milliliter (Figure 1A). SARS-CoV-2 was more stable on plastic and stainless steel than on copper and cardboard, and viable virus was detected up to 72 hours after application to these surfaces (Figure 1A), although the virus titer was greatly reduced (from 103.7 to 100.6 TCID50 per milliliter of medium after 72 hours on plastic and from 103.7 to 100.6 TCID50 per milliliter after 48 hours on stainless steel). The stability kinetics of SARS-CoV-1 were similar (from 103.4 to 100.7 TCID50 per milliliter after 72 hours on plastic and from 103.6 to 100.6 TCID50 per milliliter after 48 hours on stainless steel). On copper, no viable SARS-CoV-2 was measured after 4 hours and no viable SARS-CoV-1 was measured after 8 hours. On cardboard, no viable SARS-CoV-2 was measured after 24 hours and no viable SARS-CoV-1 was measured after 8 hours (Figure 1A). Both viruses had an exponential decay in virus titer across all experimental conditions, as indicated by a linear decrease in the log10TCID50 per liter of air or milliliter of medium over time (Figure 1B). The half-lives of SARS-CoV-2 and SARS-CoV-1 were similar in aerosols, with median estimates of approximately 1.1 to 1.2 hours and 95% credible intervals of 0.64 to 2.64 for SARS-CoV-2 and 0.78 to 2.43 for SARS-CoV-1 (Figure 1C, and Table S1 in the Supplementary Appendix). The half-lives of the two viruses were also similar on copper. On cardboard, the half-life of SARS-CoV-2 was longer than that of SARS-CoV-1. The longest viability of both viruses was on stainless steel and plastic; the estimated median half-life of SARS-CoV-2 was approximately 5.6 hours on stainless steel and 6.8 hours on plastic (Figure 1C). Estimated differences in the half-lives of the two viruses were small except for those on cardboard (Figure 1C). Individual replicate data were noticeably “noisier” (i.e., there was more variation in the experiment, resulting in a larger standard error) for cardboard than for other surfaces (Fig. S1 through S5), so we advise caution in interpreting this result. We found that the stability of SARS-CoV-2 was similar to that of SARS-CoV-1 under the experimental circumstances tested. This indicates that differences in the epidemiologic characteristics of these viruses probably arise from other factors, including high viral loads in the upper respiratory tract and the potential for persons infected with SARS-CoV-2 to shed and transmit the virus while asymptomatic. 3,4 Our results indicate that aerosol and fomite transmission of SARS-CoV-2 is plausible, since the virus can remain viable and infectious in aerosols for hours and on surfaces up to days (depending on the inoculum shed). These findings echo those with SARS-CoV-1, in which these forms of transmission were associated with nosocomial spread and super-spreading events, 5 and they provide information for pandemic mitigation efforts.

0 comments Cited 4070 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Lirong Zou, Feng Ruan, Mingxing Huang … (2020)

To the Editor: The 2019 novel coronavirus (SARS-CoV-2) epidemic, which was first reported in December 2019 in Wuhan, China, and has been declared a public health emergency of international concern by the World Health Organization, may progress to a pandemic associated with substantial morbidity and mortality. SARS-CoV-2 is genetically related to SARS-CoV, which caused a global epidemic with 8096 confirmed cases in more than 25 countries in 2002–2003. 1 The epidemic of SARS-CoV was successfully contained through public health interventions, including case detection and isolation. Transmission of SARS-CoV occurred mainly after days of illness 2 and was associated with modest viral loads in the respiratory tract early in the illness, with viral loads peaking approximately 10 days after symptom onset. 3 We monitored SARS-CoV-2 viral loads in upper respiratory specimens obtained from 18 patients (9 men and 9 women; median age, 59 years; range, 26 to 76) in Zhuhai, Guangdong, China, including 4 patients with secondary infections (1 of whom never had symptoms) within two family clusters (Table S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). The patient who never had symptoms was a close contact of a patient with a known case and was therefore monitored. A total of 72 nasal swabs (sampled from the mid-turbinate and nasopharynx) (Figure 1A) and 72 throat swabs (Figure 1B) were analyzed, with 1 to 9 sequential samples obtained from each patient. Polyester flock swabs were used for all the patients. From January 7 through January 26, 2020, a total of 14 patients who had recently returned from Wuhan and had fever (≥37.3°C) received a diagnosis of Covid-19 (the illness caused by SARS-CoV-2) by means of reverse-transcriptase–polymerase-chain-reaction assay with primers and probes targeting the N and Orf1b genes of SARS-CoV-2; the assay was developed by the Chinese Center for Disease Control and Prevention. Samples were tested at the Guangdong Provincial Center for Disease Control and Prevention. Thirteen of 14 patients with imported cases had evidence of pneumonia on computed tomography (CT). None of them had visited the Huanan Seafood Wholesale Market in Wuhan within 14 days before symptom onset. Patients E, I, and P required admission to intensive care units, whereas the others had mild-to-moderate illness. Secondary infections were detected in close contacts of Patients E, I, and P. Patient E worked in Wuhan and visited his wife (Patient L), mother (Patient D), and a friend (Patient Z) in Zhuhai on January 17. Symptoms developed in Patients L and D on January 20 and January 22, respectively, with viral RNA detected in their nasal and throat swabs soon after symptom onset. Patient Z reported no clinical symptoms, but his nasal swabs (cycle threshold [Ct] values, 22 to 28) and throat swabs (Ct values, 30 to 32) tested positive on days 7, 10, and 11 after contact. A CT scan of Patient Z that was obtained on February 6 was unremarkable. Patients I and P lived in Wuhan and visited their daughter (Patient H) in Zhuhai on January 11 when their symptoms first developed. Fever developed in Patient H on January 17, with viral RNA detected in nasal and throat swabs on day 1 after symptom onset. We analyzed the viral load in nasal and throat swabs obtained from the 17 symptomatic patients in relation to day of onset of any symptoms (Figure 1C). Higher viral loads (inversely related to Ct value) were detected soon after symptom onset, with higher viral loads detected in the nose than in the throat. Our analysis suggests that the viral nucleic acid shedding pattern of patients infected with SARS-CoV-2 resembles that of patients with influenza 4 and appears different from that seen in patients infected with SARS-CoV. 3 The viral load that was detected in the asymptomatic patient was similar to that in the symptomatic patients, which suggests the transmission potential of asymptomatic or minimally symptomatic patients. These findings are in concordance with reports that transmission may occur early in the course of infection 5 and suggest that case detection and isolation may require strategies different from those required for the control of SARS-CoV. How SARS-CoV-2 viral load correlates with culturable virus needs to be determined. Identification of patients with few or no symptoms and with modest levels of detectable viral RNA in the oropharynx for at least 5 days suggests that we need better data to determine transmission dynamics and inform our screening practices.

0 comments Cited 2460 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Temporal dynamics in viral shedding and transmissibility of COVID-19

Xi. He, Eric Lau, Peng Wu … (2020)

We report temporal patterns of viral shedding in 94 patients with laboratory-confirmed COVID-19 and modeled COVID-19 infectiousness profiles from a separate sample of 77 infector-infectee transmission pairs. We observed the highest viral load in throat swabs at the time of symptom onset, and inferred that infectiousness peaked on or before symptom onset. We estimated that 44% (95% confidence interval, 25-69%) of secondary cases were infected during the index cases' presymptomatic stage, in settings with substantial household clustering, active case finding and quarantine outside the home. Disease control measures should be adjusted to account for probable substantial presymptomatic transmission.

0 comments Cited 2147 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

N. Büchner: nikolaus.buechner@rub.de

Journal

Journal ID (nlm-ta): Somnologie (Berl)

Journal ID (iso-abbrev): Somnologie (Berl)

Title: Somnologie

Publisher: Springer Medizin (Heidelberg )

ISSN (Print): 1432-9123

ISSN (Electronic): 1439-054X

Publication date (Electronic): 22 June 2020

Pages: 1-11

Affiliations

[1 ]GRID grid.470892.0, Medizinischen Klinik I (Pneumologie, Schlaf- und Beatmungsmedizin), , Helios Klinikum Duisburg GmbH, ; An der Abtei 7–11, 47166 Duisburg, Deutschland

[2 ]Lungenzentrum Ulm, Ulm, Deutschland

[3 ]GRID grid.10253.35, ISNI 0000 0004 1936 9756, Fachkrankenhaus Kloster Grafschaft GmbH, Akademisches Lehrkrankenhaus, , Philipps-Universität Marburg, ; Schmallenberg Grafschaft, Deutschland

[4 ]Deutsche Gesellschaft für Schlafforschung und Schlafmedizin, Schwalmstadt-Treysa, Deutschland

[5 ]Neurologische Klinik Reithofpark, Medical Park, Bad Feilnbach, Deutschland

[6 ]Praxis und Schlaflabor für Innere Medizin, Pneumologie, Allergologie, Schlafmedizin, Reinbek, Deutschland

[7 ]GRID grid.489371.0, ISNI 0000 0004 0630 8065, Klinik für Pneumologie, , Krankenhaus Bethanien, ; Solingen, Deutschland

[8 ]GRID grid.6190.e, ISNI 0000 0000 8580 3777, Institut für Pneumologie, , Universität zu Köln, ; Köln, Deutschland

Article

Publisher ID: 253

DOI: 10.1007/s11818-020-00253-w

PMC ID: 7306656

SO-VID: 2c8d1f74-e811-4eba-839b-8c2ec4f90a41

License:

This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

Read this article at

Abstract

Translated abstract

Related collections

Novel Coronavirus Disease COVID-19

Most cited references 31

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Temporal dynamics in viral shedding and transmissibility of COVID-19

Author and article information

Contributors

Journal

Affiliations

Article

History

Categories

Comments

Comment on this article

Similar content 346

Cited by 2

Most referenced authors 1,320